Triplet Therapies in Chronic Lymphocytic Leukemia.

IF 2.7 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2025-07-23 DOI:10.1016/j.hoc.2025.05.001

Jacob D Soumerai, Matthew S Davids

引用次数: 0

Abstract

Triplet therapy regimens, which we define as the combination of a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib), BCL2 inhibitor (venetoclax or sonrotoclax), and a CD20 antibody (obinutuzumab), have been developed in chronic lymphocytic leukemia (CLL). Herein, we comprehensively review the available clinical data for triplet regimens in treatment-naïve CLL, including an evidence-based discussion of the role of TP53 aberrancy in patients receiving triplet therapies, and of retreatment options after frontline triplet therapy. We also review ongoing trials with potential to further define the role of triplet therapies in treatment-naïve CLL.

查看原文本刊更多论文

慢性淋巴细胞白血病的三联疗法。

我们将三重治疗方案定义为BTK抑制剂（ibrutinib、acalabrutinib、zanubrutinib或pirtobrutinib）、BCL2抑制剂（venetoclax或sonrotoclax）和CD20抗体（obinutuzumab）的联合治疗，已开发用于慢性淋巴细胞白血病（CLL）。在此，我们全面回顾了treatment-naïve CLL中三胞胎治疗方案的现有临床数据，包括基于证据的TP53异常在接受三胞胎治疗的患者中的作用，以及一线三胞胎治疗后的再治疗选择。我们还回顾了正在进行的试验，这些试验有可能进一步确定三联疗法在treatment-naïve CLL中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.